Paracoff (Paracetamol 500 mg + Caffeine 65 mg): Uses, Dosage & Side Effects
A prescription-only combination analgesic pairing paracetamol with caffeine as an analgesic adjuvant for mild to moderate pain
Paracoff is a prescription combination analgesic containing 500 mg of paracetamol and 65 mg of caffeine in a single film-coated tablet. The paracetamol component provides central pain relief and fever reduction, while the caffeine component acts as an analgesic adjuvant, enhancing pain relief by approximately 40 percent compared with paracetamol alone. Paracoff is intended for short-term management of mild to moderate pain such as tension headache, menstrual pain, dental pain, musculoskeletal pain, and pain following minor surgical or dental procedures. Like all paracetamol-containing medicines, Paracoff carries a risk of severe liver injury if taken in excess.
Quick Facts: Paracoff
Key Takeaways
- Paracoff combines paracetamol 500 mg (a central analgesic and antipyretic) with caffeine 65 mg (an analgesic adjuvant that enhances paracetamol's pain-relieving effect by approximately 40 percent).
- The usual adult dose is 1–2 film-coated tablets every 4–6 hours as needed, with a maximum of 8 tablets per 24 hours (providing 4,000 mg paracetamol and 520 mg caffeine).
- Do not use any additional paracetamol-containing products while taking Paracoff, and minimise other caffeine sources such as coffee, tea, cola, energy drinks, and caffeinated cold and flu remedies.
- Paracoff is generally not recommended during pregnancy or breastfeeding because of the caffeine content; plain paracetamol should be preferred when analgesia is needed in these groups.
- Paracetamol overdose can cause severe, potentially fatal liver damage with symptoms that may be delayed 24–72 hours; seek immediate emergency care after any suspected overdose, even if you feel well.
What Is Paracoff and What Is It Used For?
Paracoff is a fixed-dose combination analgesic classified under ATC code N02BE51 (paracetamol, combinations excluding psycholeptics). Each film-coated tablet contains two active ingredients that act through complementary pharmacological mechanisms to produce a stronger analgesic effect than either component alone. The rationale for combining paracetamol with a low dose of caffeine dates back to the 1960s, when clinical studies first demonstrated that caffeine functions as an analgesic adjuvant, meaning that although caffeine itself is not a pain reliever at these doses, it reliably potentiates the effect of other analgesics.
The principal indication for Paracoff is the short-term symptomatic treatment of mild to moderate acute pain. Typical clinical situations include tension-type headache, episodic migraine (without aura), dysmenorrhoea (menstrual pain), dental pain including pain after tooth extraction, musculoskeletal pain such as low back pain and myalgia, post-operative pain following minor surgical procedures, and symptomatic pain and fever during upper respiratory tract infections and influenza. Paracoff is not intended for chronic daily pain management and should not be used for prolonged periods without medical reassessment.
The paracetamol component provides the core analgesic and antipyretic effect. Paracetamol inhibits cyclooxygenase (COX) activity primarily in the central nervous system, reducing the synthesis of prostaglandins involved in pain signalling and thermoregulation. It also activates descending serotonergic inhibitory pathways from the brainstem, and may interact with the endocannabinoid and transient receptor potential (TRP) systems. Because paracetamol does not significantly inhibit peripheral COX enzymes, it lacks the anti-inflammatory and antiplatelet effects of NSAIDs, which gives it a more favourable gastrointestinal and haemostatic profile in most patients.
The caffeine component adds a series of distinct pharmacological actions that enhance analgesia. Caffeine is a methylxanthine that antagonises adenosine receptors, particularly the A1 and A2A subtypes, leading to increased central nervous system arousal, vasoconstriction of cerebral blood vessels, and modulation of pain perception. A 2014 Cochrane systematic review concluded that the addition of caffeine (≥100 mg) to standard analgesic doses of paracetamol or ibuprofen provides a small but clinically relevant improvement in the proportion of patients experiencing meaningful pain relief. Even at the lower adjuvant dose of 65 mg per tablet used in Paracoff, pooled clinical data suggest a measurable enhancement of analgesic efficacy, particularly in tension-type headache and dental pain.
An important clinical consideration is that Paracoff is dispensed as a prescription-only (Rx) medicine rather than as an over-the-counter product. Prescription status allows a healthcare professional to verify the diagnosis, screen for contraindications, review concurrent medications, and ensure that dosing is tailored to the individual patient. It also helps limit unmonitored long-term use, which is particularly relevant for caffeine-containing products because daily use can lead to physiological tolerance, dependence, and rebound headache (medication-overuse headache) in susceptible patients.
What Should You Know Before Taking Paracoff?
Contraindications
Paracoff must not be used in several specific situations. Safe prescribing depends on identifying these contraindications before the first dose is taken.
- Hypersensitivity: Known allergy (including anaphylaxis, angioedema or severe skin reaction) to paracetamol, caffeine, or any of the excipients listed in the product labelling.
- Severe hepatic insufficiency: Active severe liver disease, decompensated cirrhosis, or acute hepatitis. Paracetamol is hepatically metabolised and even therapeutic doses may precipitate further liver injury in severe hepatic failure.
- Severe renal impairment with anuria: Where elimination of paracetamol metabolites is severely impaired, specialist supervision is required and lower doses with extended intervals are generally needed.
- Concomitant use of other paracetamol-containing medicines: To avoid accidental overdose, Paracoff should not be taken together with other products containing paracetamol (including many cold and flu remedies, combination analgesics, and prescription opioid-paracetamol combinations).
- Children under 12 years of age: The fixed caffeine content makes Paracoff unsuitable for young children, for whom weight-based plain paracetamol dosing is safer.
Warnings and Precautions
Never exceed 8 Paracoff tablets in 24 hours. Higher doses do not provide better pain relief and carry a significant risk of severe liver damage. Liver injury may not cause symptoms for 24–72 hours. Seek emergency medical care immediately after any suspected overdose, even if you feel well.
Before starting Paracoff, inform your doctor or pharmacist about all existing medical conditions, including conditions that may not seem related to pain relief. Several situations call for particular caution and may require dose adjustment, closer monitoring, or choice of an alternative analgesic:
- Impaired liver function: Chronic liver disease, compensated cirrhosis, hepatitis, or Gilbert's syndrome. The maximum daily dose of paracetamol should be reduced, typically to 2,000 mg/day (equivalent to 4 Paracoff tablets), and dosing intervals extended to every 6–8 hours.
- Impaired kidney function: Moderate to severe renal impairment (creatinine clearance below 30 ml/min) requires extended dosing intervals and, in some cases, dose reduction because of accumulation of paracetamol glucuronide and sulphate metabolites.
- Chronic alcohol use: Regular alcohol intake induces hepatic CYP2E1, which increases production of the toxic paracetamol metabolite NAPQI. This lowers the threshold for liver injury, and patients with alcohol use disorder should not exceed 2,000 mg paracetamol per day.
- Malnutrition or low body weight (<50 kg): Glutathione stores (which detoxify NAPQI) are depleted in malnutrition, raising hepatotoxicity risk. Use a reduced maximum daily dose under medical guidance.
- Severe infection or sepsis: High anion gap metabolic acidosis has been reported at therapeutic doses of paracetamol in critically ill patients, particularly in combination with flucloxacillin.
- Cardiovascular conditions: Severe uncontrolled hypertension, tachyarrhythmias, unstable angina, and recent myocardial infarction. The caffeine component can increase heart rate, raise blood pressure, and trigger palpitations.
- Anxiety, panic disorder, and insomnia: Caffeine can worsen anxiety symptoms, precipitate panic attacks, and impair sleep quality. In such patients, caffeine-free analgesia (plain paracetamol) is generally preferred.
- Hyperthyroidism: The caffeine component may exacerbate symptoms such as tachycardia, tremor, and agitation.
- Peptic ulcer disease: While paracetamol itself is generally well tolerated in patients with peptic ulcer, caffeine can stimulate gastric acid secretion and may worsen symptoms.
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency: There is a small risk of haemolytic anaemia with paracetamol exposure in this inherited condition.
- Medication-overuse headache: Regular use of any analgesic (including paracetamol and caffeine combinations) on 10 or more days per month for more than three months can itself cause chronic daily headache, which resolves only on withdrawal of the offending medication.
Paracetamol is present in a very large number of over-the-counter and prescription products, including combination cold and flu remedies, sinus medications, menstrual pain products, and opioid-paracetamol tablets. Always read labels and ingredient lists carefully. Accidental duplication of paracetamol-containing products is a leading cause of unintentional paracetamol overdose and acute liver failure.
Pregnancy and Breastfeeding
Paracoff is generally not recommended for use during pregnancy or breastfeeding because of its caffeine content. Although the paracetamol component alone is regarded as the safest first-line analgesic in pregnancy by the WHO, NICE, ACOG and EMA, high caffeine intake during pregnancy has been associated with adverse outcomes in several large observational studies.
A systematic review published in the BMJ Evidence-Based Medicine (2020) reported a dose-response relationship between maternal caffeine consumption and increased risks of miscarriage, stillbirth, low birth weight, and small-for-gestational-age infants. On this basis, most international authorities recommend limiting total daily caffeine intake during pregnancy to no more than 200 mg per day from all sources. Two Paracoff tablets already provide 130 mg caffeine, and the maximum daily dose of 8 tablets provides 520 mg caffeine — well above the pregnancy limit. If analgesia is required during pregnancy, plain paracetamol 500 mg tablets at the lowest effective dose are preferred.
Caffeine is also secreted into breast milk, and levels in breastfeeding infants can be significant because neonates metabolise caffeine very slowly (clearance may take several days compared with a few hours in adults). This can lead to irritability, poor feeding, and disturbed sleep in the infant. For nursing mothers who require regular analgesia, plain paracetamol is preferred. Occasional use of Paracoff may be acceptable if the benefits clearly outweigh the risks, but this decision should be made in consultation with a doctor or midwife.
Driving and Operating Machinery
At recommended doses, Paracoff is not expected to impair the ability to drive or operate machinery. The paracetamol component does not cause sedation, and the caffeine component may actually improve alertness. However, some individuals may experience side effects such as dizziness, tremor or jitteriness, particularly at higher doses or when combined with additional caffeinated drinks. If you experience such symptoms, refrain from driving or using hazardous machinery until they resolve.
How Does Paracoff Interact with Other Drugs?
Paracoff interacts with medications through two distinct mechanisms: interactions with the paracetamol component (most commonly involving hepatic metabolism and NAPQI production), and interactions with the caffeine component (primarily through CYP1A2 metabolism and central nervous system effects). Always inform your doctor, pharmacist or nurse about all medications, herbal remedies, and supplements you are taking before starting Paracoff.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Warfarin and other coumarin anticoagulants | Regular use of paracetamol (>2 g/day for several days) may enhance the anticoagulant effect, increasing INR and risk of bleeding | Occasional use is usually safe. Limit regular use to 2 g paracetamol (4 tablets) per day for maximum 5 days and monitor INR closely. Inform your anticoagulant clinic. |
| Flucloxacillin | Combined use can precipitate high anion gap metabolic acidosis, especially in patients with sepsis, renal impairment or malnutrition | Use with caution. Seek immediate medical attention for rapid deep breathing, nausea, vomiting or loss of appetite. |
| Carbamazepine, phenytoin, phenobarbital, primidone | Enzyme-inducing antiepileptic drugs accelerate paracetamol metabolism, increasing production of the hepatotoxic metabolite NAPQI | Use the lowest effective paracetamol dose. Avoid prolonged or high-dose use without specialist input. |
| Rifampicin, St John's wort | Strong enzyme inducers that significantly increase paracetamol metabolism and NAPQI formation | Reduced paracetamol doses advised. Medical supervision is recommended for regular use. |
| Fluvoxamine | Potent CYP1A2 inhibitor that increases caffeine plasma concentrations up to 5-fold, prolonging its half-life | Avoid combination. Seek caffeine-free alternatives for pain relief. |
| Ciprofloxacin, norfloxacin and other fluoroquinolones | Inhibit CYP1A2-mediated caffeine metabolism, leading to increased caffeine levels, palpitations, tremor and insomnia | Limit Paracoff dose and avoid additional caffeine sources during fluoroquinolone therapy. |
| Lithium | Caffeine increases renal lithium clearance; discontinuation may precipitate lithium toxicity by reducing excretion | Monitor lithium levels when starting or stopping regular Paracoff use. Avoid abrupt changes. |
| MAO inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide) | Combined use can precipitate hypertensive crisis due to reduced caffeine metabolism and enhanced sympathomimetic activity | Avoid Paracoff during MAOI therapy and for 14 days after stopping an MAOI. |
| Clozapine | Caffeine inhibits clozapine metabolism and can significantly raise clozapine plasma levels, increasing risk of toxicity | Use with caution and maintain consistent caffeine intake. Psychiatric specialist input recommended. |
Minor and Moderate Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Theophylline and aminophylline | Both theophylline and caffeine are methylxanthines sharing CYP1A2 metabolism; combined use may cause additive toxicity including nausea, tremor, tachycardia and seizures | Avoid unnecessary combination; monitor for xanthine toxicity if concurrent use is required. |
| Oral contraceptives | Ethinylestradiol inhibits CYP1A2 and slows caffeine clearance, prolonging caffeine half-life by roughly 40 percent | Patients may experience stronger caffeine effects. Consider reducing additional caffeine intake. |
| Cimetidine | Inhibits caffeine metabolism, modestly increasing plasma levels and half-life | Limit additional caffeine sources; consider dose reduction if sensitive to caffeine effects. |
| Probenecid | Reduces clearance of paracetamol by inhibiting glucuronide conjugation, increasing paracetamol blood levels | Consider reducing paracetamol dose or extending dosing intervals when taking probenecid concurrently. |
| Cholestyramine | Reduces absorption of paracetamol from the gut if taken together | Take Paracoff at least 1 hour before or 4 hours after cholestyramine. |
| Beta-blockers and ACE inhibitors | The caffeine component may partially blunt the antihypertensive effect in some patients | Monitor blood pressure when Paracoff is used regularly in hypertensive patients. |
| Ephedrine, pseudoephedrine and other sympathomimetics | Additive cardiovascular stimulation; may cause palpitations, hypertension, anxiety and tremor | Avoid combining Paracoff with decongestant cold and flu remedies containing pseudoephedrine. |
| Metoclopramide and domperidone | Accelerate gastric emptying, increasing the rate of paracetamol absorption | Generally beneficial; may lead to faster onset of pain relief. No dose adjustment usually required. |
Avoid alcohol while taking Paracoff. Regular alcohol use induces the CYP2E1 enzyme, which dramatically increases production of the toxic paracetamol metabolite NAPQI. Patients who drink alcohol regularly may experience liver damage at doses lower than those considered safe for the general population. Caffeine does not counteract the intoxicating effects of alcohol, and the combination can mask sedation and lead to risky behaviour.
What Is the Correct Dosage of Paracoff?
Paracoff dosing must respect the upper limits of both active ingredients. The maximum daily paracetamol dose (4,000 mg) determines the absolute upper bound of 8 Paracoff tablets per 24 hours, while the total caffeine load (520 mg from 8 tablets) influences how the dose is distributed through the day, particularly to avoid disturbing sleep.
Adults and Adolescents Over 12 Years (Body Weight >50 kg)
Standard Oral Dosing
Single dose: 1 to 2 film-coated tablets (500–1,000 mg paracetamol and 65–130 mg caffeine)
Dosing interval: Every 4 to 6 hours as required
Maximum single dose: 2 tablets (1,000 mg paracetamol / 130 mg caffeine)
Maximum daily dose: 8 tablets (4,000 mg paracetamol / 520 mg caffeine) in any 24-hour period
Duration of use: Limit continuous use to no more than 3 consecutive days. If pain persists or worsens, consult a healthcare professional.
Paracoff film-coated tablets should be swallowed whole with a glass of water, ideally not in the last 6 hours before bedtime to reduce the risk of caffeine-induced insomnia. The tablets may be taken with or without food. Taking Paracoff with food may delay the onset of action slightly but does not alter the overall analgesic efficacy.
Children Under 12 Years
Paracoff is not suitable for children under 12 years of age because of its fixed caffeine content. Paediatric analgesia should use weight-based dosing of plain paracetamol (10–15 mg/kg every 4–6 hours, maximum 60 mg/kg/day) in age-appropriate formulations such as oral suspensions.
Elderly Patients (Over 65 Years)
Older adults often have reduced hepatic and renal function as well as increased sensitivity to both paracetamol and caffeine. Most clinical guidelines recommend that patients over 65 years (or weighing less than 50 kg) limit daily paracetamol intake to a maximum of 3,000 mg, equivalent to 6 Paracoff tablets per day. The caffeine component may also contribute to insomnia, anxiety, palpitations, urinary frequency, and falls in frail elderly patients. Consider starting at the lower end of the dose range (1 tablet) and increasing only if needed.
Hepatic and Renal Impairment
Paracoff should be used cautiously or avoided in patients with liver or kidney disease. In mild to moderate hepatic impairment, including compensated cirrhosis and Gilbert's syndrome, the maximum paracetamol dose should be reduced to 2,000 mg per day (4 Paracoff tablets) with minimum 6-hour intervals between doses. Severe hepatic impairment (decompensated cirrhosis, acute hepatitis) is a contraindication.
For moderate renal impairment (creatinine clearance 30–60 ml/min) dosing intervals should be at least 6 hours. For severe renal impairment (creatinine clearance <30 ml/min) intervals should be at least 8 hours and a reduced maximum daily dose is advisable. Caffeine metabolism is minimally affected by renal function but accumulates modestly in severe kidney disease.
Missed Dose
Because Paracoff is taken on an as-needed basis for pain, a missed dose is rarely clinically significant. If you are taking Paracoff at regular intervals and miss a dose, take it as soon as you remember, provided at least 4 hours have passed since your last dose. Do not take a double dose to compensate for a missed one. If it is nearly time for your next dose, skip the missed dose and continue with the regular schedule.
Overdose
Paracoff overdose is a medical emergency. Contact your local emergency services or poison control centre immediately if you suspect an overdose, even if you feel well. Early administration of the antidote N-acetylcysteine dramatically improves outcomes.
The paracetamol component is by far the most dangerous aspect of Paracoff overdose. Hepatotoxicity can occur after a single ingestion of more than 150 mg/kg of paracetamol (approximately 7.5 g in a 50 kg adult, or 10 g in an average-weight adult). For reference, 15 Paracoff tablets contain 7,500 mg paracetamol. Repeated supratherapeutic doses (staggered overdose) can also cause serious liver injury even when individual doses remain below the acute toxic threshold.
The mechanism of paracetamol hepatotoxicity involves accumulation of the reactive metabolite NAPQI (N-acetyl-p-benzoquinone imine), which is normally neutralised by hepatic glutathione. When paracetamol is taken in excess, glutathione stores are depleted, and NAPQI binds covalently to hepatocellular proteins, producing centrilobular hepatic necrosis. Clinical toxicity classically evolves through four phases: phase I (0–24 hours) with nausea, vomiting and malaise; phase II (24–72 hours) with right upper quadrant pain, rising transaminases and coagulopathy; phase III (72–96 hours) with peak hepatic injury, possible encephalopathy and multi-organ failure; and phase IV (after 96 hours) with either recovery or progressive hepatic failure.
The antidote for paracetamol overdose is intravenous N-acetylcysteine (NAC), which replenishes glutathione and directly neutralises NAPQI. NAC is most effective when given within 8 hours of ingestion, but may still provide benefit up to 24 hours or later, including in patients with established liver injury. Treatment is guided by nomograms (such as the Rumack-Matthew nomogram) based on the paracetamol plasma concentration and time since ingestion.
Caffeine overdose from Paracoff is less immediately life-threatening than paracetamol overdose but can be symptomatic. Caffeine doses above approximately 500 mg may cause tachycardia, palpitations, tremor, anxiety, insomnia, nausea, vomiting, diuresis and gastrointestinal discomfort. Very high caffeine doses (>1 g) can produce severe arrhythmias, seizures, hyperthermia, rhabdomyolysis, hypokalaemia and cardiovascular collapse. Treatment of caffeine toxicity is supportive, with benzodiazepines for agitation and seizures, beta-blockade for sustained tachyarrhythmia, and intensive care monitoring in severe cases.
What Are the Side Effects of Paracoff?
Side effects of Paracoff arise from either the paracetamol component, the caffeine component, or the combination. At therapeutic doses, the paracetamol part of the tablet is generally very well tolerated and produces very few adverse effects. Most of the side effects experienced at normal doses are caffeine-related. The frequencies below are based on the MedDRA convention applied to pharmacovigilance data for paracetamol-caffeine combinations.
Common
- Nervousness, restlessness, jitteriness: From the caffeine component, particularly in caffeine-sensitive individuals
- Insomnia and sleep disturbance: Especially when doses are taken late in the day
- Palpitations and mild tachycardia: Caffeine-induced sympathetic activation
- Dyspepsia, nausea, abdominal discomfort: Caffeine can stimulate gastric acid secretion
- Diuresis (increased urination): Mild and transient caffeine effect
Uncommon
- Headache (including rebound or medication-overuse headache): Typically with prolonged daily use
- Tremor, particularly fine hand tremor: Caffeine-related
- Anxiety and irritability: More likely in patients with underlying anxiety disorders
- Dizziness: Usually self-limiting
- Vomiting
- Mild elevation of liver enzymes: Generally reversible on stopping the medication
Rare
- Allergic skin reactions: Hives (urticaria), rash, pruritus
- Angioedema: Swelling of the face, lips, tongue or throat
- Bronchospasm: Wheezing and breathlessness, particularly in aspirin-sensitive individuals
- Hepatotoxicity: Elevated liver enzymes, jaundice or hepatitis (primarily associated with overdose or repeated supratherapeutic dosing)
- Significant cardiovascular effects: Sustained tachycardia, hypertension or arrhythmia from the caffeine component
Very Rare
- Thrombocytopenia: Reduced platelet count causing unusual bleeding or bruising
- Leukopenia, neutropenia or agranulocytosis: Reduced white blood cells with fever, sore throat and risk of infection
- Haemolytic anaemia: Particularly in patients with G6PD deficiency
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Life-threatening skin reactions requiring immediate emergency care
- Acute generalised exanthematous pustulosis (AGEP): Widespread pustular rash
- Anaphylaxis: Severe systemic allergic reaction
- Acute kidney injury: Very rare with therapeutic doses; more likely with chronic high-dose use
Frequency Not Known
- High anion gap metabolic acidosis: Reported in patients with sepsis, severe renal impairment or malnutrition, particularly with concurrent flucloxacillin use
- Caffeine withdrawal syndrome: Headache, fatigue and drowsiness on abrupt cessation after regular use
Stop taking Paracoff and call emergency services immediately if you experience: swelling of the face, lips, tongue or throat; difficulty breathing or swallowing; severe skin rash with blistering or peeling; unexplained bleeding or bruising; yellowing of the skin or eyes (jaundice); dark urine or pale stools; chest pain or severe palpitations; or symptoms of possible overdose.
Many side effects reported with Paracoff are attributable to the caffeine dose and may be reduced by taking Paracoff earlier in the day, avoiding additional dietary caffeine, and drinking plenty of water. Caffeine-sensitive individuals may benefit from a caffeine-free alternative such as plain paracetamol. Patients who experience any unexpected symptoms while taking Paracoff should report them to their doctor or pharmacist. You can also report suspected side effects directly to your national pharmacovigilance authority (for example, the MHRA Yellow Card scheme in the UK, the FDA MedWatch programme in the US, or the EMA EudraVigilance system in Europe). Reporting side effects contributes to the ongoing monitoring of the benefit-risk balance of medicines.
How Should You Store Paracoff?
Proper storage preserves the efficacy and stability of Paracoff film-coated tablets until the expiry date. Because paracetamol can undergo hydrolysis in the presence of moisture and caffeine can be sensitive to prolonged heat, a few simple storage precautions are important.
- Temperature: Store at room temperature, generally below 25°C (77°F). Avoid storing tablets in excessively hot or humid environments such as bathrooms, near the kitchen stove, or in a car glovebox during summer. Do not refrigerate or freeze.
- Packaging: Keep the tablets in the original blister pack or tablet container, with the cap tightly closed if supplied in a bottle. The blister foil protects each tablet from moisture, air and light. Only remove a tablet from the blister immediately before use.
- Light protection: Avoid storing Paracoff in direct sunlight or under bright artificial light. The film coating helps protect the tablet but prolonged light exposure is best avoided.
- Child safety: Keep Paracoff securely out of the sight and reach of children and adolescents. Because paracetamol overdose is a leading cause of acute liver failure in children, consider storing the medication in a locked cabinet. Never leave tablets on bedside tables or kitchen counters.
- Expiry date: Do not use Paracoff after the expiry date printed on the carton and blister. The expiry date refers to the last day of the month shown. Expired paracetamol may have reduced potency and, in some cases, produce degradation products.
- Safe disposal: Do not dispose of unwanted medicines via household waste, sinks or toilets. Return unused or expired Paracoff tablets to your pharmacy, which participates in medicine take-back programmes that protect the environment from pharmaceutical contamination.
If you notice any change in the appearance of the tablets, such as discoloration, cracking, softening, or an unusual smell, do not use them and return the product to the pharmacy. These changes can indicate that the medicine has been exposed to adverse conditions and may no longer be safe or effective.
What Does Paracoff Contain?
Paracoff is a fixed-dose oral combination product. Each film-coated tablet delivers two active pharmaceutical ingredients working through complementary mechanisms, supported by a set of pharmaceutically inert excipients that ensure tablet stability, disintegration, palatability and ease of swallowing.
Active Ingredients per Tablet
Paracetamol (acetaminophen): 500 mg per film-coated tablet. Paracetamol is a central analgesic and antipyretic acting primarily through inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with additional modulation of descending serotonergic and endocannabinoid pathways.
Caffeine (anhydrous): 65 mg per film-coated tablet. Caffeine is a methylxanthine and non-selective adenosine A1/A2A receptor antagonist that acts as an analgesic adjuvant, enhancing the pain-relieving effect of paracetamol.
Typical Inactive Ingredients (Excipients)
The specific excipients used in Paracoff film-coated tablets may vary slightly by manufacturer or batch, but a typical formulation will include the following categories of excipient. Always refer to the patient information leaflet supplied with your specific pack for the exact list.
- Tablet core excipients: Pregelatinised starch, maize starch, povidone, microcrystalline cellulose, croscarmellose sodium or sodium starch glycolate (disintegrants), and magnesium stearate or stearic acid (lubricants).
- Film-coating agents: Hypromellose, titanium dioxide (E171) as an opacifier, macrogol (polyethylene glycol), and talc. Coloured coatings may additionally contain pharmaceutical-grade pigments such as iron oxides.
If you have known allergies or intolerances to specific excipients (for example, certain starches, povidone, film-coating polymers or colourings), always read the full ingredient list on the product packaging or in the patient information leaflet before the first dose. Your pharmacist can help you identify suitable alternative formulations if necessary.
Paracoff film-coated tablets do not contain lactose, gluten or animal-derived ingredients in most formulations, making them suitable for patients with lactose intolerance, coeliac disease, or following vegetarian or vegan diets. However, composition can vary between manufacturers, so patients with specific dietary concerns should verify the ingredient list on the actual product supplied.
Marketing Authorisation and Manufacturer
Paracoff is supplied as a prescription-only medicine (Rx) under the brand name Paracoff. Detailed information on the marketing authorisation holder, manufacturer and local availability is provided in the country-specific Summary of Product Characteristics (SmPC) and patient information leaflet that accompany each pack. Because prescribing status and product composition can differ between countries, always follow the instructions in your own prescription and the leaflet supplied with the pack dispensed by your pharmacy.
Frequently Asked Questions About Paracoff
Paracoff is a prescription combination analgesic containing 500 mg paracetamol and 65 mg caffeine per film-coated tablet. It is used for the short-term treatment of mild to moderate pain including tension-type headache, episodic migraine, menstrual pain, dental pain (including pain after tooth extraction), musculoskeletal pain such as low back pain, and pain following minor surgery. The caffeine component acts as an analgesic adjuvant that enhances the pain-relieving effect of paracetamol by approximately 40 percent. Paracoff is intended for occasional short-term use rather than continuous long-term therapy.
Each Paracoff tablet contains 65 mg of caffeine, which is roughly equivalent to the caffeine in a small cup of filter coffee or a mug of strong tea. The maximum single dose of two tablets provides 130 mg caffeine, and the maximum daily dose of eight tablets provides 520 mg caffeine — higher than the 400 mg upper limit generally recommended for healthy adults. Sensitivity varies, but many people experience increased alertness, mild jitteriness, palpitations or difficulty sleeping at these doses. To reduce sleep disturbance, avoid taking Paracoff within 6 hours of bedtime and limit additional caffeinated drinks and foods.
The maximum daily dose for healthy adults weighing more than 50 kg is 8 film-coated tablets in any 24-hour period, providing a total of 4,000 mg paracetamol and 520 mg caffeine. Individual doses must be separated by at least 4 hours, and the maximum single dose is 2 tablets. Do not exceed this limit even if pain is not controlled — contact your doctor instead. Lower maximum doses apply to elderly patients (over 65 years), people weighing less than 50 kg, and patients with liver disease, kidney disease, malnourishment or chronic alcohol use, typically 6 tablets (3,000 mg paracetamol) per day or less as advised by a healthcare professional.
Paracoff is generally not recommended during pregnancy or breastfeeding because of its caffeine content. Although the paracetamol component alone is regarded as the safest first-line analgesic in pregnancy, high caffeine intake during pregnancy has been associated with increased risk of miscarriage, stillbirth and low birth weight. Current guidance limits total daily caffeine in pregnancy to 200 mg, which can be exceeded quickly with a Paracoff-based regimen. In breastfeeding, caffeine passes into breast milk and infants metabolise it very slowly, potentially causing irritability and poor sleep. Plain paracetamol 500 mg tablets are preferred for pain relief during pregnancy and breastfeeding.
Paracoff overdose is a medical emergency. Contact emergency services or your local poison control centre immediately if you suspect an overdose, even if you feel well. The paracetamol component can cause severe, potentially fatal liver damage, with symptoms that may be delayed 24 to 72 hours. The antidote N-acetylcysteine (NAC) is highly effective when given within 8 hours of ingestion but still beneficial later. High doses of caffeine may cause additional symptoms including tachycardia, palpitations, tremor, nausea, vomiting, hyperthermia, agitation, seizures and cardiac arrhythmias. Bring the medication packaging with you to the hospital so that the exact ingredients and quantity can be determined.
You should minimise or avoid additional sources of caffeine while taking Paracoff. Each tablet already contains 65 mg of caffeine, and the maximum daily dose provides 520 mg caffeine. International guidance limits total daily caffeine to 400 mg in healthy adults and 200 mg in pregnant women. Combining Paracoff with coffee, tea, cola, energy drinks, chocolate or caffeine-containing supplements and cold and flu remedies can cause insomnia, anxiety, headache, palpitations, tremor, gastrointestinal upset and elevated blood pressure. If you normally consume a lot of caffeine, consider switching to decaffeinated beverages for the duration of your Paracoff treatment.
Paracoff film-coated tablets usually begin to relieve pain within 30 to 60 minutes, with peak analgesic effect at approximately 1 to 2 hours after ingestion. The caffeine component is absorbed rapidly and may shorten the time to meaningful pain relief compared with plain paracetamol. The analgesic effect typically lasts 4 to 6 hours. If effective pain relief is not achieved within 2 hours of a full dose, do not take additional tablets — contact your doctor instead. Taking Paracoff with food may slightly delay absorption but does not reduce overall effectiveness.
Paracoff can generally be taken alongside ibuprofen or other NSAIDs (such as naproxen or diclofenac) because they work through different mechanisms, providing additive analgesia. However, you must not combine Paracoff with any other product that contains paracetamol — this is a leading cause of accidental paracetamol overdose. Always read ingredient labels on cold and flu remedies, combination analgesics, menstrual pain products, and opioid-paracetamol tablets. If you take regular anticoagulation, aspirin, or corticosteroids, consult your doctor before combining Paracoff with NSAIDs. If you have a history of peptic ulcer, kidney disease, asthma or cardiovascular disease, NSAIDs may not be suitable.
References
This article is based on current international medical guidelines, regulatory documents, and peer-reviewed research. All sources meet evidence level 1A standards.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Paracetamol is listed as an essential medicine for pain and palliative care.
- European Medicines Agency (EMA). Paracetamol and Caffeine – Summary of Product Characteristics. EMA/CHMP; 2024. Regulatory reference for indications, dosing, contraindications and safety data for paracetamol-caffeine combinations.
- U.S. Food and Drug Administration (FDA). Acetaminophen and Caffeine Combination Drug Labeling and Safety Communication. FDA; 2023.
- Joint Formulary Committee. British National Formulary (BNF) – Paracetamol and Caffeine Monographs. London: BMJ Group and Pharmaceutical Press; 2024.
- National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summaries: Analgesia – Mild-to-Moderate Pain. NICE; 2023.
- Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database of Systematic Reviews. 2014;(12):CD009281. doi:10.1002/14651858.CD009281.pub3
- Laska EM, Sunshine A, Mueller F, et al. Caffeine as an analgesic adjuvant. JAMA. 1984;251(13):1711-1718. Seminal study establishing caffeine as an analgesic adjuvant.
- Mazaleuskaya LL, Sangkuhl K, Thorn CF, et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenetics and Genomics. 2015;25(8):416-426. doi:10.1097/FPC.0000000000000150
- Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacological Reviews. 2018;70(2):384-411. doi:10.1124/pr.117.014407
- European Food Safety Authority (EFSA). Scientific Opinion on the Safety of Caffeine. EFSA Journal. 2015;13(5):4102. Upper safe intake limits of caffeine for adults and pregnant women.
- Bateman DN, Carroll R, Pettie J, et al. Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment. British Journal of Clinical Pharmacology. 2014;78(3):610-618. doi:10.1111/bcp.12362
- James A, Wadhwa H, Soehn H, et al. Maternal caffeine consumption and pregnancy outcomes: a narrative review with implications for advice to mothers and mothers-to-be. BMJ Evidence-Based Medicine. 2021;26(3):114-115.
- International Headache Society. The International Classification of Headache Disorders, 3rd edition (ICHD-3) – Medication-overuse headache. Cephalalgia. 2018;38(1):1-211.
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology and drug safety.
Content developed by iMedic's medical writing team based on current international guidelines (WHO, EMA, FDA, BNF, NICE) and peer-reviewed pharmacological research on paracetamol-caffeine combination analgesics.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in clinical pharmacology and internal medicine.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.